DE60041343D1 - Oxa- und thiazolderivate sowie ihre verwendung gegen diabetes und fettsucht - Google Patents

Oxa- und thiazolderivate sowie ihre verwendung gegen diabetes und fettsucht

Info

Publication number: DE60041343D1
Authority: DE; Germany
Prior art keywords: oxa; use against; against diabetes; fat support; thiazol derivatives
Prior art date: 1999-09-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60041343T

Other languages

English (en)

Inventor

Peter T Cheng

Pratik Devasthale

Yoon T Jeon

Sean Chen

Hao Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-22

Filing date

2000-09-19

Publication date

2009-02-26

2000-09-19 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2009-02-26 Application granted granted Critical

2009-02-26 Publication of DE60041343D1 publication Critical patent/DE60041343D1/de

2020-09-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE60041343T 1999-09-22 2000-09-19 Oxa- und thiazolderivate sowie ihre verwendung gegen diabetes und fettsucht Expired - Lifetime DE60041343D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15540099P	1999-09-22	1999-09-22
PCT/US2000/025710 WO2001021602A1 (en)	1999-09-22	2000-09-19	Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents

Publications (1)

Publication Number	Publication Date
DE60041343D1 true DE60041343D1 (de)	2009-02-26

Family

ID=22555274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60041343T Expired - Lifetime DE60041343D1 (de)	1999-09-22	2000-09-19	Oxa- und thiazolderivate sowie ihre verwendung gegen diabetes und fettsucht

Country Status (28)

Country	Link
US (1)	US7579479B2 (de)
EP (1)	EP1218361B1 (de)
JP (2)	JP4332315B2 (de)
KR (1)	KR100682419B1 (de)
CN (1)	CN1289490C (de)
AR (1)	AR025756A1 (de)
AT (1)	ATE420080T1 (de)
AU (1)	AU782031B2 (de)
BR (1)	BR0014189A (de)
CA (1)	CA2388452C (de)
CO (1)	CO5200832A1 (de)
DE (1)	DE60041343D1 (de)
EG (1)	EG24169A (de)
ES (1)	ES2319097T3 (de)
HK (1)	HK1049337B (de)
HU (1)	HUP0204416A3 (de)
IL (2)	IL147939A0 (de)
MX (1)	MXPA02001847A (de)
MY (1)	MY138525A (de)
NO (1)	NO322500B1 (de)
NZ (1)	NZ516820A (de)
PE (1)	PE20010643A1 (de)
PL (1)	PL364986A1 (de)
RU (2)	RU2327692C2 (de)
TR (1)	TR200200732T2 (de)
TW (4)	TWI302149B (de)
WO (1)	WO2001021602A1 (de)
ZA (1)	ZA200200937B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
TWI302149B (en) *	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
CA2405709A1 (en)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Albumin fusion proteins
AR030379A1 (es) *	2000-08-22	2003-08-20	Novartis Ag	Combinaciones
AR033390A1 (es) *	2000-08-22	2003-12-17	Novartis Ag	Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
WO2002051441A1 (fr)	2000-12-26	2002-07-04	Sankyo Company, Limited	Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
EP1394154A4 (de)	2001-03-23	2005-05-18	Takeda Pharmaceutical	Fünfgliedriges heterocyclisches alkansäurederivat
US7105556B2 (en)	2001-05-30	2006-09-12	Bristol-Myers Squibb Company	Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
EP1424330B1 (de) *	2001-08-10	2011-09-28	Nippon Chemiphar Co., Ltd.	Aktivator für den peroxisome proliferator-responsiven rezeptor delta
WO2003040114A1 (en) *	2001-11-06	2003-05-15	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TW200300681A (en) *	2001-11-12	2003-06-16	Ono Pharmaceutical Co	Carboxylic acid derivative compound and medicament containing same as active ingredient
CN1326519C (zh) *	2001-12-14	2007-07-18	诺沃挪第克公司	化合物及其降低激素－敏感性脂肪酶活性的用途
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2545090T3 (es)	2001-12-21	2015-09-08	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina y GCSF
TW200305415A (en) *	2002-03-22	2003-11-01	Novartis Ag	Combination of organic compounds
US6716842B2 (en)	2002-04-05	2004-04-06	Warner-Lambert Company, Llc	Antidiabetic agents
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
EP1656368A4 (de) *	2002-07-09	2009-08-26	Bristol Myers Squibb Co	Als antidiabetika und mittel gegen obesitas geeignete substituierte heterocyclische derivate und verfahren
CA2490972C (en) *	2002-07-09	2012-05-29	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7232828B2 (en)	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
TWI343915B (en)	2002-10-07	2011-06-21	Hoffmann La Roche	Chirale ppar agonists
US7098235B2 (en)	2002-11-14	2006-08-29	Bristol-Myers Squibb Co.	Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) *	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10311984A1 (de) *	2003-03-12	2004-09-23	Freie Universität Berlin	Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten
KR20060061300A (ko) *	2003-06-13	2006-06-07	라보라토리오스 에스.에이.엘.브이.에이.티., 에스.에이.	ＰＰＡＲγ 조절제로서의 벤즈아미드
WO2005000309A2 (en) *	2003-06-27	2005-01-06	Ionix Pharmaceuticals Limited	Chemical compounds
WO2005049589A2 (en) *	2003-10-14	2005-06-02	Cadila Healthcare Limited	Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
SI1679074T1 (sl)	2003-10-24	2011-04-29	Santen Pharmaceutical Co Ltd	Terapevtsko sredstvo za keratokonjuktivno motnjo
EP1681054A1 (de)	2003-10-29	2006-07-19	Santen Pharmaceutical Co., Ltd.	Therapeutisches mittel für keratokonjuntiva-erkrankungen
US7829552B2 (en)	2003-11-19	2010-11-09	Metabasis Therapeutics, Inc.	Phosphorus-containing thyromimetics
WO2005095364A1 (ja) *	2004-03-30	2005-10-13	Daiichi Pharmaceutical Co. Ltd.	フェノキシ酢酸誘導体及びそれを用いた医薬
JP2007230868A (ja) *	2004-03-30	2007-09-13	Dai Ichi Seiyaku Co Ltd	二環性化合物及びそれを用いた医薬
EP1586573B1 (de)	2004-04-01	2007-02-07	Sanofi-Aventis Deutschland GmbH	Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
US7618981B2 (en) *	2004-05-06	2009-11-17	Cytokinetics, Inc.	Imidazopyridinyl-benzamide anti-cancer agents
US7378427B2 (en)	2004-06-18	2008-05-27	Wyeth	Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines
KR100739367B1 (ko) *	2004-07-14	2007-07-16	크리스탈지노믹스(주)	설파마이드 유도체 및 이를 함유하는 지방대사 촉진용약학적 조성물
TW200608967A (en)	2004-07-29	2006-03-16	Sankyo Co	Pharmaceutical compositions containing with diabetic agent
AR051446A1 (es)	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7635699B2 (en)	2004-12-29	2009-12-22	Bristol-Myers Squibb Company	Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en)	2004-12-29	2009-09-15	Bristol-Myers Squibb Company	Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US20060235028A1 (en)	2005-04-14	2006-10-19	Li James J	Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
WO2006117743A1 (en) *	2005-05-03	2006-11-09	Ranbaxy Laboratories Limited	Substituted aromatic compounds as antidiabetic agents
US7521557B2 (en)	2005-05-20	2009-04-21	Bristol-Myers Squibb Company	Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
EP1943215A2 (de)	2005-10-31	2008-07-16	Brystol-Myers Squibb Company	Inhibitoren von dipeptidylpeptidase iv auf pyrrolidinyl-beta-aminoamidbasis und verfahren
FR2896159B1 (fr)	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2897536A1 (fr) *	2006-02-17	2007-08-24	Galderma Res & Dev	Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
US7919598B2 (en)	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
US8318941B2 (en)	2006-07-06	2012-11-27	Bristol-Myers Squibb Company	Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7910747B2 (en)	2006-07-06	2011-03-22	Bristol-Myers Squibb Company	Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7795291B2 (en) *	2006-07-07	2010-09-14	Bristol-Myers Squibb Company	Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US20080009534A1 (en) *	2006-07-07	2008-01-10	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US7727978B2 (en)	2006-08-24	2010-06-01	Bristol-Myers Squibb Company	Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
AU2007293885A1 (en)	2006-09-07	2008-03-13	Takeda Gmbh	Combination treatment for diabetes mellitus
KR100958831B1 (ko) *	2006-09-19	2010-05-24	주식회사유한양행	헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물
AU2007318092B2 (en) *	2006-10-26	2013-01-10	Amgen Inc.	Calcium receptor modulating agents
PE20090185A1 (es)	2007-03-22	2009-02-28	Bristol Myers Squibb Co	Formulaciones farmaceuticas que contienen un inhibidor sglt2
US8546394B2 (en)	2007-04-17	2013-10-01	Bristol-Myers Squibb Company	Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
PE20090696A1 (es)	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
US8604245B2 (en)	2007-06-04	2013-12-10	Ben-Gurion University Of The Negev Research And Development Authority	Tri-aryl compounds and compositions comprising the same
US8222285B2 (en)	2007-06-11	2012-07-17	Bristol-Myers Squibb Company	1,3-dihydroxy substituted phenylamide glucokinase activators
CA2725680A1 (en) *	2008-05-30	2009-12-03	Takeda Pharmaceutical Company Limited	Heterocyclic compound
WO2010004319A1 (en) *	2008-07-07	2010-01-14	Astrazeneca Ab	Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt
KR101036406B1 (ko) *	2008-10-24	2011-05-24	박란	축구공
EP2196476A1 (de)	2008-12-10	2010-06-16	Novartis Ag	Antikörperformulierung
WO2010093601A1 (en)	2009-02-10	2010-08-19	Metabasis Therapeutics, Inc.	Novel sulfonic acid-containing thyromimetics, and methods for their use
CA2780938A1 (en)	2009-11-13	2011-05-19	Bristol-Myers Squibb Company	Reduced mass metformin formulations
EP2498758B1 (de)	2009-11-13	2018-07-25	AstraZeneca AB	Zweischichtige tablettenformulierungen
AU2010319377B2 (en)	2009-11-13	2014-10-23	Astrazeneca Ab	Immediate release tablet formulations
TWI562775B (en)	2010-03-02	2016-12-21	Lexicon Pharmaceuticals Inc	Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
EP2558461B1 (de)	2010-04-14	2015-12-02	Bristol-Myers Squibb Company	Neuartige glucokinase-aktivatoren und verfahren zu ihrer verwendung
US20130224296A1 (en)	2010-09-03	2013-08-29	Bristol-Myers Squibb Company	Drug Formulations Using Water Soluble Antioxidants
TWI631963B (zh)	2011-01-05	2018-08-11	雷西肯製藥股份有限公司	包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2607480C2 (ru)	2011-02-01	2017-01-10	Бристол-Майерс Сквибб Компани	Фармацевтические композиции, содержащие аминосоединение
ES2634716T3 (es)	2011-05-31	2017-09-28	Celgene International Ii Sàrl	Nuevos estabilizantes y moduladores del receptor GLP-1
EP2574607A1 (de)	2011-09-06	2013-04-03	F. Hoffmann-La Roche AG	PDE 10-Modulatoren
TR201908247T4 (tr)	2012-11-20	2019-06-21	Lexicon Pharmaceuticals Inc	Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
JP6573604B2 (ja)	2013-06-11	2019-09-11	セルジーンインターナショナルツーエスエーアールエル	新規なｇｌｐ−１レセプターモジュレーター
CN103694195B (zh) *	2013-09-18	2016-04-06	华东师范大学	芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途
JP6657101B2 (ja)	2013-11-05	2020-03-04	ベングリオンユニバーシティオブザネガフリサーチアンドディベロップメントオーソリティ	糖尿病及びそれから生じる疾患合併症の治療のための化合物
KR102497644B1 (ko)	2014-12-10	2023-02-08	리셉토스 엘엘씨	Glp-1 수용체 조절제
SG10201913709QA (en) *	2015-04-02	2020-03-30	Ascentawits Pharmaceuticals Ltd	Nitrobenzyl derivatives of anti-cancer agents
CN113039176A (zh)	2018-09-26	2021-06-25	莱西肯医药有限公司	N-(1-((2-(二甲基氨基)乙基)氨基)-2-甲基-1-氧代丙-2-基)-4-(4-(2-甲基-5-((2s,3r,4r,5s,6r)-3,4,5-三羟基-6-(甲硫基)四氢-2h-吡喃-2-基)苯甲基)苯基)丁酰胺的结晶形式及其合成方法
CN114981251B (zh) *	2020-01-21	2023-11-21	深圳信立泰药业股份有限公司	一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途
JP7407651B2 (ja) *	2020-04-20	2024-01-04	東ソー・ファインケム株式会社	３－アセトキシスチレンの製造方法
WO2024100051A1 (en)	2022-11-08	2024-05-16	Genfit	Ppar-alpha/gamma agonist for use in the treatment of liver failure

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5036079A (en) *	1989-12-07	1991-07-30	Pfizer Inc.	Hypoglycemic thiazolidinedione derivatives
US5250677A (en) *	1990-06-04	1993-10-05	Bristol-Myers Squibb Company	Azetidin-2-one derivatives as serine protease inhibitors
US5110812A (en) *	1990-06-04	1992-05-05	Bristol-Myers Squibb Co.	Azetidin-2-one derivatives as serine protease inhibitors
US5037819A (en) *	1990-06-04	1991-08-06	Bristol-Myers Squibb Company	Azetidin-2-one derivatives as serine protease inhibitors
US5175283A (en) *	1990-06-04	1992-12-29	Bristol-Myers Squibb Company	Azetidin-2-one derivatives as serine protease inhibitors
JPH05213884A (ja)	1991-06-14	1993-08-24	Upjohn Co:The	新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
GB9113628D0 (en)	1991-06-25	1991-08-14	Ici Plc	Heterocyclic derivatives
US5232945A (en) *	1992-07-20	1993-08-03	Pfizer Inc.	3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5776983A (en) *	1993-12-21	1998-07-07	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
JPH08325263A (ja) *	1995-05-31	1996-12-10	Sumitomo Metal Ind Ltd	新規２−アミノ−３−フェニルプロピオン酸誘導体
JP2000504021A (ja)	1996-02-02	2000-04-04	メルクエンドカンパニーインコーポレーテッド	糖尿病及び関連疾患状態を治療する方法
AU1856997A (en)	1996-02-02	1997-08-22	Merck & Co., Inc.	Method for raising hdl cholesterol levels
ATE236137T1 (de)	1996-02-02	2003-04-15	Merck & Co Inc	Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
WO1997027857A1 (en)	1996-02-02	1997-08-07	Merck & Co., Inc.	Antidiabetic agents
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
JP3215048B2 (ja) *	1996-04-03	2001-10-02	日本たばこ産業株式会社	プロピオン酸誘導体及びその用途
ZA973850B (en) *	1996-05-06	1997-12-02	Reddy Research Foundation	Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
JP2000515133A (ja)	1996-07-01	2000-11-14	イーライ・リリー・アンド・カンパニー	血糖降下性および脂質低下性の化合物
IL121203A (en)	1996-07-01	2001-04-30	Lilly Co Eli	1, 2, 3, 4-tetrahydroisoquinidines, process for their preparation and pharmaceutical compositions containing the same for treating hyperglycemia and hyperlipidemia
JP2001511767A (ja)	1996-12-23	2001-08-14	メルクエンドカンパニーインコーポレーテッド	糖尿病薬
AU8559598A (en)	1997-08-08	1999-03-01	Ono Pharmaceutical Co. Ltd.	Gamma-type regulators for peroxisome proliferator-activated receptor
WO1999011255A1 (fr)	1997-08-28	1999-03-11	Ono Pharmaceutical Co., Ltd.	Regulateurs du recepteur active par les agents de proliferation des peroxysomes
AU9002798A (en)	1997-09-19	1999-04-12	Ono Pharmaceutical Co. Ltd.	Fused or nonfused benzene compounds
JP2001520193A (ja)	1997-10-17	2001-10-30	アヴェンティスファーマシューティカルズプロダクツインコーポレイテッド	キノリン誘導体の治療的使用
US6130214A (en)	1997-10-27	2000-10-10	Dr. Reddy's Research Foundation	Benzothiazin and benzoxazin derivatives; their preparation and uses
DE69941777D1 (de) *	1998-03-10	2010-01-21	Ono Pharmaceutical Co	Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
ATE286032T1 (de)	1998-04-23	2005-01-15	Reddys Lab Ltd Dr	Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9817118D0 (en) *	1998-08-07	1998-10-07	Glaxo Group Ltd	Pharmaceutical compounds
MXPA01010880A (es)	1999-04-28	2002-05-06	Aventis Pharma Gmbh	Derivados de acido diarilico como ligandos de receptor ppar.
EE200100558A (et)	1999-04-28	2002-12-16	Aventis Pharma Deutschland Gmbh	Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
TWI302149B (en) *	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method

2000
- 2000-09-18 TW TW094102034A patent/TWI302149B/zh not_active IP Right Cessation
- 2000-09-18 TW TW089119155A patent/TWI260321B/zh not_active IP Right Cessation
- 2000-09-18 TW TW093126012A patent/TW200514783A/zh unknown
- 2000-09-18 TW TW093126011A patent/TW200528436A/zh unknown
- 2000-09-19 JP JP2001524981A patent/JP4332315B2/ja not_active Expired - Fee Related
- 2000-09-19 CN CNB008131406A patent/CN1289490C/zh not_active Expired - Fee Related
- 2000-09-19 DE DE60041343T patent/DE60041343D1/de not_active Expired - Lifetime
- 2000-09-19 CA CA002388452A patent/CA2388452C/en not_active Expired - Fee Related
- 2000-09-19 AT AT00965172T patent/ATE420080T1/de not_active IP Right Cessation
- 2000-09-19 AU AU75935/00A patent/AU782031B2/en not_active Ceased
- 2000-09-19 EP EP00965172A patent/EP1218361B1/de not_active Expired - Lifetime
- 2000-09-19 HU HU0204416A patent/HUP0204416A3/hu unknown
- 2000-09-19 RU RU2005117879/04A patent/RU2327692C2/ru not_active IP Right Cessation
- 2000-09-19 WO PCT/US2000/025710 patent/WO2001021602A1/en active IP Right Grant
- 2000-09-19 ES ES00965172T patent/ES2319097T3/es not_active Expired - Lifetime
- 2000-09-19 NZ NZ516820A patent/NZ516820A/en unknown
- 2000-09-19 BR BR0014189-5A patent/BR0014189A/pt not_active Application Discontinuation
- 2000-09-19 KR KR1020027003723A patent/KR100682419B1/ko not_active IP Right Cessation
- 2000-09-19 RU RU2002108928/04A patent/RU2279427C2/ru not_active IP Right Cessation
- 2000-09-19 TR TR2002/00732T patent/TR200200732T2/xx unknown
- 2000-09-19 EG EG20001198A patent/EG24169A/xx active
- 2000-09-19 PL PL00364986A patent/PL364986A1/xx not_active Application Discontinuation
- 2000-09-19 IL IL14793900A patent/IL147939A0/xx active IP Right Grant
- 2000-09-19 MX MXPA02001847A patent/MXPA02001847A/es active IP Right Grant
- 2000-09-21 CO CO00071835A patent/CO5200832A1/es not_active Application Discontinuation
- 2000-09-21 MY MYPI20004412A patent/MY138525A/en unknown
- 2000-09-22 PE PE2000000994A patent/PE20010643A1/es not_active Application Discontinuation
- 2000-09-22 AR ARP000104989A patent/AR025756A1/es not_active Application Discontinuation
2002
- 2002-01-31 IL IL147939A patent/IL147939A/en not_active IP Right Cessation
- 2002-02-01 ZA ZA200200937A patent/ZA200200937B/en unknown
- 2002-03-21 NO NO20021408A patent/NO322500B1/no not_active IP Right Cessation
2003
- 2003-02-28 HK HK03101528.6A patent/HK1049337B/zh not_active IP Right Cessation
2005
- 2005-08-22 US US11/155,965 patent/US7579479B2/en not_active Expired - Lifetime
2008
- 2008-12-22 JP JP2008325065A patent/JP2009102360A/ja active Pending

Also Published As

Publication number	Publication date
AR025756A1 (es)	2002-12-11
IL147939A (en)	2008-03-20
NO20021408D0 (no)	2002-03-21
EG24169A (en)	2008-09-10
RU2327692C2 (ru)	2008-06-27
PE20010643A1 (es)	2001-08-18
HUP0204416A3 (en)	2006-01-30
NO322500B1 (no)	2006-10-16
WO2001021602A1 (en)	2001-03-29
HK1049337B (zh)	2007-07-27
IL147939A0 (en)	2002-08-14
TWI302149B (en)	2008-10-21
JP4332315B2 (ja)	2009-09-16
US20070015797A1 (en)	2007-01-18
TR200200732T2 (tr)	2002-10-21
NZ516820A (en)	2004-11-26
RU2005117879A (ru)	2006-11-20
ATE420080T1 (de)	2009-01-15
HUP0204416A2 (hu)	2003-04-28
EP1218361A1 (de)	2002-07-03
CO5200832A1 (es)	2002-09-27
JP2009102360A (ja)	2009-05-14
AU7593500A (en)	2001-04-24
RU2002108928A (ru)	2004-01-10
AU782031B2 (en)	2005-06-30
JP2003509503A (ja)	2003-03-11
BR0014189A (pt)	2002-08-20
CN1289490C (zh)	2006-12-13
US7579479B2 (en)	2009-08-25
TW200514783A (en)	2005-05-01
TWI260321B (en)	2006-08-21
KR100682419B1 (ko)	2007-02-28
ZA200200937B (en)	2003-07-30
CN1374955A (zh)	2002-10-16
EP1218361B1 (de)	2009-01-07
KR20020047179A (ko)	2002-06-21
TW200538446A (en)	2005-12-01
PL364986A1 (en)	2004-12-27
CA2388452C (en)	2007-04-03
NO20021408L (no)	2002-05-14
HK1049337A1 (en)	2003-05-09
TW200528436A (en)	2005-09-01
ES2319097T3 (es)	2009-05-04
MXPA02001847A (es)	2002-10-23
CA2388452A1 (en)	2001-03-29
MY138525A (en)	2009-06-30
RU2279427C2 (ru)	2006-07-10

Publication	Publication Date	Title
DE60041343D1 (de)	2009-02-26	Oxa- und thiazolderivate sowie ihre verwendung gegen diabetes und fettsucht
DE60020701D1 (de)	2005-07-14	Thiazol- und oxazol-derivate und ihre pharmazeutische verwendung
ATE254123T1 (de)	2003-11-15	Benzazolderivate und ihre verwendung als jnk modulatoren
DE60039539D1 (de)	2008-08-28	4-aminopiperidin-derivate und ihre verwendung als arzneimittel
DE60027479D1 (de)	2006-05-24	Harzstruktur und ihre verwendung
DE50009607D1 (de)	2005-03-31	Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung
DE60139477D1 (de)	2009-09-17	2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
ATE252091T1 (de)	2003-11-15	Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
DE69926800D1 (de)	2005-09-22	Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE60208351D1 (de)	2006-02-02	Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de)	2009-02-12	Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de)	2010-10-21	Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60315892D1 (de)	2007-10-04	Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
ATE375987T1 (de)	2007-11-15	Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60038200D1 (de)	2008-04-17	ren Herstellung und Verwendung
ATE284886T1 (de)	2005-01-15	Benzimidazolderivate, ihre herstellung und therapeutische verwendung
ATE231869T1 (de)	2003-02-15	Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
DE602004028934D1 (de)	2010-10-14	Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DE60027927D1 (de)	2006-06-14	Harzstruktur und ihre verwendung
ATE384054T1 (de)	2008-02-15	Substituierte benzoxazinones und ihre verwendung
ATE419248T1 (de)	2009-01-15	Phenylsubstituierte 4-hydroxy-tetrahydropyridone und ihre verwendung als schädlingsbekämpungsmittel und herbizide
DE60321372D1 (de)	2008-07-10	3-phenylpyridoindolderivate, ihre herstellung und verwendung
DE50008549D1 (de)	2004-12-09	Triazolotriazinone und ihre verwendung
ATE264315T1 (de)	2004-04-15	Aminothiazolderivate und ihre verwendung als crf- rezeptor-liganden
DE69902387D1 (de)	2002-09-05	Oxadiazolinderivate und ihre verwendung als insektizide

Legal Events

Date	Code	Title	Description
2010-01-28	8364	No opposition during term of opposition